drugset / Trial / NCT01553357
Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia
Phase 2
Completed
23 enrolled
IRCCS Centro di Riferimento Oncologico della Basilicata
Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, multicenter, exploratory, single arm, two-stage study aiming to explore efficacy and safety of lenalidomide and dexamethasone combination (LD) as first line therapy in previously untreated patients with primary Plasma Cell leukemia (PPCL).
Timeline
- Start
- 2009-03
- Primary completion
- 2011-08
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |